Testing effectiveness (Phase 2)WithdrawnNCT02397395
What this trial is testing
An Efficacy, Safety, Tolerability and Pharmacokinetics Study of 12 Weeks Treatment With Simeprevir and Daclatasvir in Participants With Chronic Hepatitis C Virus Genotype 1b or 4 Infection and Either Severe Renal Impairment or End-stage Renal Disease on Hemodialysis.
Who this might be right for
Renal ImpairmentEnd-stage Renal Disease
Janssen R&D Ireland